Detalles de la búsqueda
1.
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
N Engl J Med
; 381(17): 1609-1620, 2019 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31475794
2.
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation
; 141(5): 338-351, 2020 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31736337
3.
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
Circulation
; 140(17): 1369-1379, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31510768
4.
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Eur Heart J
; 38(15): 1132-1143, 2017 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28158398
5.
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Circulation
; 133(23): 2254-62, 2016 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27143684
6.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med
; 371(11): 993-1004, 2014 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25176015
7.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Am Heart J
; 188: 35-41, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577679
8.
Geographic variations in the PARADIGM-HF heart failure trial.
Eur Heart J
; 37(41): 3167-3174, 2016 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354044
9.
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Circulation
; 131(1): 54-61, 2015 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403646
10.
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Eur Heart J
; 36(38): 2576-84, 2015 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26231885
11.
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
Circulation
; 134(22): 1785-1787, 2016 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27895026
12.
Health-related quality of life outcomes in PARAGON-HF.
Eur J Heart Fail
; 24(12): 2264-2274, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36394533
13.
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
J Am Heart Assoc
; 10(17): e022069, 2021 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33998278
14.
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE.
Clin Res Cardiol
; 110(8): 1334-1349, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34101002
15.
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
Eur J Heart Fail
; 23(9): 1518-1524, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34101308
16.
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week.
J Am Coll Cardiol
; 77(15): 1922-1933, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33858628
17.
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
J Am Heart Assoc
; 10(4): e019238, 2021 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33522249
18.
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
Eur J Heart Fail
; 23(5): 776-784, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33609066
19.
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Circ Heart Fail
; 14(4): e007901, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33866828
20.
Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
J Am Coll Cardiol
; 75(3): 245-254, 2020 01 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31726194